BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Kissei Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Kissei Pharmaceutical's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06161974-2857@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT06161974)
DESCRIPTION:Olutasidenib\, phase 2\, Glioma.\nStudy: Study of Olutasidenib 
 and Temozolomide in HGG\nEstimated primary completion: June 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/olutasidenib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06161974
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604064-2857@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Olutasidenib: Phase 2 readout est. (NCT07604064)
DESCRIPTION:Olutasidenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Clin
 ical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia\nEstima
 ted primary completion: September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olutasidenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07604064
URL:https://assetmemo.bio/drug/olutasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
